SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Keel Infrastructure Corp. engages in building artificial intelligence focused data centers and energy assets. It focuses on infrastructure and energy required to support high-performance computing and artificial intelligence workloads. The company was founded on April 1, 2026 and is headquartered in New York, NY.

Keel Infrastructure Corp.

Keel Infrastructure Corp

Keel Infrastructure Corp is trending as investors bet on the companys pivot from crypto mining to AI-focused data center infrastructure. The community is actively discussing rumors of imminent lease contracts and positive technical momentum, with many highlighting the potential for a rerating as the company integrates into major market indices.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape is seeing significant market momentum following a multi-year joint research agreement with Honda, which validates the scalability and performance of its solid-state battery platform. Community sentiment is largely bullish, with investors actively discussing the company's expanding OEM ecosystem, potential applications in AI data centers, and the strategic importance of securing a second major automotive partner beyond Volkswagen.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending as investors digest positive Phase 3 VELA-program data, which demonstrates durable efficacy and a clean safety profile for sonelokimab in treating hidradenitis suppurativa. The community is actively discussing the stock's best-in-class potential and the likelihood of a strategic buyout as the company moves toward BLA submission.

Definium Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.

Definium Therapeutics Inc.

Definium Therapeutics is trending due to positive topline Phase 3 data for its depression treatment, triggering significant investor interest and ongoing debate regarding its potential for commercial success against established psychedelic peers. Community discussions center on the company's clinical trial catalysts, cash runway, and the binary nature of upcoming data readouts in the competitive mental health space.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals is attracting intense community interest as high volume and unusual pre-market activity fuel speculation regarding a potential buyout or upcoming catalyst for the AUR200 pipeline. Investors are closely monitoring CEO Kevin Tang's significant share accumulation while debating the impact of ongoing patent litigation and the strategic silence from the new management team.

Chevron Corp. engages in the provision of oil and gas energy solutions. It provides crude oil and natural gas, manufactures transportation fuels, lubricants, petrochemicals, and additives, and develops technologies that enhance business and the industry. It operates through the Upstream and Downstream segments. The Upstream segment consists of the exploration, development, and production of crude oil and natural gas, the liquefaction, transportation, and regasification associated with liquefied natural gas, the transporting of crude oil by major international oil export pipelines, the processing, transporting, storage, and marketing of natural gas, and a gas-to-liquids plant. The Downstream segment consists of the refining of crude oil into petroleum products, the marketing of crude oil and refined products, the transporting of crude oil and refined products by pipeline, marine vessel, motor equipment, and rail car, and the manufacturing and marketing of commodity petrochemicals and plastics for industrial uses and fuel & lubricant additives. The company was founded on September 10, 1879 and is headquartered in Houston, TX.

Chevron Corp.

Chevron (CVX) is trending as investors weigh strong operational performance and dividend reliability against the geopolitical risks of the Strait of Hormuz conflict. The community is actively debating the stock's resilience, with many noting that persistent supply disruptions and energy security themes continue to act as key catalysts for the sector.

Roundhill ETF Trust - Roundhill Memory ETF

The Roundhill Memory ETF (DRAM) is trending as investors capitalize on the structural AI-driven demand for HBM and storage, despite broader market volatility and uncertainty surrounding major upcoming IPOs. Community sentiment remains overwhelmingly bullish, with many participants framing the current price action as a strategic entry point for a long-term re-rating of the memory sector beyond its traditional cyclical history.

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Regenxbio Inc

Regenxbio is in the spotlight following the FDA's decision to issue a Complete Response Letter (CRL) for its Hunter syndrome gene therapy, NAVSUNLI, effectively rejecting the current application while demanding additional data. Investors are now shifting their focus toward the company's long-term pipeline potential, specifically the RGX-202 program for Duchenne muscular dystrophy and the ongoing wet AMD collaboration with AbbVie, as the community debates whether current valuations adequately reflect the company's remaining cash runway and development milestones.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk is trending as investors aggressively bid up memory stocks, fueled by reports of structural storage shortages and AI-driven data center demand. The community is actively debating the sustainability of this parabolic run, with some traders highlighting the stock's record-setting RSI as a sign of an overheating market while others point to institutional re-rating as evidence of a sustained supercycle.

SPDR Series Trust - State Street SPDR S&P Biotech ETF

SPDR S&P Biotech ETF

The SPDR S&P Biotech ETF (XBI) is trending as investors monitor a rotation into the biotech sector, fueled by anticipation of key clinical trial readouts and potential M&A activity despite broader market volatility. Community discourse remains heavily focused on the high-risk, high-reward profiles of individual companies like SLS and IBRX, with many users tracking short interest, pipeline milestones, and regulatory catalysts.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Delcath Systems Announces Two ASCO 2026 Investigator Initiated Trials-in-Progress Abstracts

Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced the publication of two investigator-initiated trials-in-progress abstracts on May 21, 2026. These abstracts will be presented at the 2026...

Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Delcath Systems, Inc. (Nasdaq: DCTH) (the Company or Delcath), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Companys Compensation Committee, as material...

Delcath Systems to Participate at the H.C. Wainwright 4th Annual BioConnect Investor Conference

Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that management will be attending the H.C. Wainwright 4th Annual BioConnect Investor Conference on Tuesday, May 19, 2026 at Nasdaq in New...

Delcath Systems, Inc. (DCTH) Reports Q1 Loss, Misses Revenue Estimates

Delcath Systems (DCTH) delivered earnings and revenue surprises of -200.00% and -0.42%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Delcath Systems Announces Presentation of New Data on Percutaneous Hepatic Perfusion with Melphalan in Liver-Dominant Metastatic Breast Cancer at ESMO Breast Cancer 2026

Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that new data from a retrospective...

Delcath Systems (DCTH) to Release Quarterly Earnings on Thursday

Delcath Systems (NASDAQ:DCTH) will be releasing its Q1 2026 earnings before the market opens on Thursday, May 7. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-7-delcath-systems-inc-stock...

Delcath Systems to Host First Quarter 2026 Earnings Call

Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on May 7, 2026, at 8:30 AM Eastern Time to discuss results for its first quarter ended March 31, 2026...

Delcath Systems, Inc. (NASDAQ:DCTH) Given Consensus Rating of "Moderate Buy" by Brokerages

Delcath Systems, Inc. (NASDAQ:DCTH - Get Free Report) has been given an average rating of "Moderate Buy" by the six brokerages that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating and five have issued a buy rating on the com...

JPMorgan Chase & Co. Decreases Position in Delcath Systems, Inc. $DCTH

JPMorgan Chase & Co. cut its position in Delcath Systems, Inc. (NASDAQ:DCTH - Free Report) by 92.6% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 12,501 shares of the company's stock after selling 155,744 shares during the period. JPMorgan Chase & Co.'s ho...

Delcath Systems (NASDAQ:DCTH) Stock Price Up 0.3% - Time to Buy?

Delcath Systems (NASDAQ:DCTH) Shares Up 0.3% - Should You Buy...

Delcath Systems, Inc. is an oncology company, which engages in the treatment of primary and metastatic liver cancers. Its products include CHEMOSAT and HEPZATO. The company was founded on August 5, 1988 and is headquartered in Queensbury, NY.

Delcath Systems Inc

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$11.69
Prev Close	$11.93
Open	$12.09
Dividend Yield	0.00%
50-Day Moving Average	$11.01
Beta	1.29
Avg. Volume	494,796.60
PE Ratio	1,948.33

52-Week High	$14.48
52-Week Low	$8.12
Market Capitalization	$403.56M
EPS (Annual)	$0.0676
Price to Book	3.57
Revenue Per Employee	$546,352.56

DCTHDelcath Systems Inc

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest DCTH News